Dexamethasone induces docetaxel and cisplatin resistance partially through up-regulating Krüppel-like factor 5 in triplenegative breast cancer

Oncotarget

Volumn 8, Issue 7, 2017, Pages 11555-11565

  Li, Zhen ^a,b,c   Dong, Jian ^a   Zou, Tianning ^a   Du, Chengzhi ^b   Li, Siyuan ^b   Chen, Ceshi ^b   Liu, Rong ^b   Wang, Kunhua ^a,c  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b KUNMING INSTITUTE OF ZOOLOGY   (China)

^c Kunming Engineering Technology Center of Digestive Disease   (China)

Author keywords

Dex; Drug resistance; GR; KLF5; TNBC

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; GLUCOCORTICOID RECEPTOR; KRUPPEL LIKE FACTOR 5; MESSENGER RNA; SULFORHODAMINE B; ANTIINFLAMMATORY AGENT; KRUPPEL LIKE FACTOR; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BREAST CARCINOGENESIS; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; COLORIMETRY; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG RESPONSE; FEMALE; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM;

ANTI-INFLAMMATORY AGENTS; CISPLATIN; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; TAXOIDS; UP-REGULATION;

EID: 85012894082     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.14135     Document Type: Article

References (46)

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016.
2. Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. The Lancet Oncology. 2014; 15:e279-289.
3. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. The New England journal of medicine. 2010; 363:1938-1948.
4. de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. Journal of cancer research and clinical oncology. 2011; 137:183-192.
5. Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A. Triplenegative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer treatment reviews. 2010; 36:206-215.
6. Clark O, Botrel TE, Paladini L, Ferreira MB. Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis. Core evidence. 2014; 9:1-11.
7. Yadav BS, Chanana P, Jhamb S. Biomarkers in triple negative breast cancer: A review. World journal of clinical oncology. 2015; 6:252-263.
8. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, Group EGW. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology. 2012; 23 Suppl 7:vii11-19.
9. Mustacchi G, De Laurentiis M. The role of taxanes in triplenegative breast cancer: literature review. Drug Des Devel Ther. 2015; 9:4303-4318.
10. Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. Journal of controlled release. 2015; 200:138-157.
11. Wang H, Li M, Rinehart JJ, Zhang R. Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Cancer chemotherapy and pharmacology. 2004; 53:459-467.
12. Henzi I, Walder B, Tramer MR. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesthesia & Analgesia. 2000; 90:186-194.
13. Narayanan S, Srinivas S, Feldman D. Androgenglucocorticoid interactions in the era of novel prostate cancer therapy. Nature reviews Urology. 2016; 13:47-60.
14. Stringer-Reasor EM, Baker GM, Skor MN, Kocherginsky M, Lengyel E, Fleming GF, Conzen SD. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015; 138:656-662.
15. Liu R, Zhou Z, Zhao D, Chen C. The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation. Molecular endocrinology. 2011; 25:1137-1144.
16. Ziemer LT, Pennica D, Levine AJ. Identification of a mouse homolog of the human BTEB2 transcription factor as a beta-catenin-independent Wnt-1-responsive gene. Mol Cell Biol. 2001; 21:562-574.
17. Taneyhill L, Pennica D. Identification of Wnt responsive genes using a murine mammary epithelial cell line model system. BMC developmental biology. 2004; 4:1.
18. Dong J-T, Chen C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cellular and molecular life sciences. 2009; 66:2691-2706.
19. Zhang Z, Teng CT. Phosphorylation of Kruppel-like factor 5 (KLF5/IKLF) at the CBP interaction region enhances its transactivation function. Nucleic acids research. 2003; 31:2196-2208.
20. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature genetics. 2008; 40:499-507.
21. Tong D, Czerwenka K, Heinze G, Ryffel M, Schuster E, Witt A, Leodolter S, Zeillinger R. Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clinical Cancer Research. 2006; 12:2442-2448.
22. Takagi K, Miki Y, Onodera Y, Nakamura Y, Ishida T, Watanabe M, Inoue S, Sasano H, Suzuki T. Krüppel-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens. Endocrine-related cancer. 2012; 19:741-750.
23. Bateman NW, Tan D, Pestell RG, Black JD, Black AR. Intestinal tumor progression is associated with altered function of KLF5. The Journal of biological chemistry. 2004; 279:12093-12101.
24. Zheng H-Q, Zhou Z, Huang J, Chaudhury L, Dong J-T, Chen C. Krüppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1. Oncogene. 2009; 28:3702-3713.
25. Xia H, Wang C, Chen W, Zhang H, Chaudhury L, Zhou Z, Liu R, Chen C. Kruppel-like factor 5 transcription factor promotes microsomal prostaglandin E2 synthase 1 gene transcription in breast cancer. The Journal of biological chemistry. 2013; 288:26731-26740.
26. Liu R, Zheng HQ, Zhou Z, Dong JT, Chen C. KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization. The Journal of biological chemistry. 2009; 284:16791-16798.
27. Frigo DE, Sherk AB, Wittmann BM, Norris JD, Wang Q, Joseph JD, Toner AP, Brown M, McDonnell DP. Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro. Mol Endocrinol. 2009; 23:1385-1396.
28. Chen C, Zhou Y, Zhou Z, Sun X, Otto KB, Uht RM, Dong J-T. Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells. Gene. 2004; 330:133-142.
29. Cheng X, Yan Y, Chen JL, Ma ZL, Yang RH, Wang G, Chuai M, Ka Ho Lee K, Yang X. Dexamethasone Exposure Accelerates Endochondral Ossification of Chick Embryos Via Angiogenesis. Toxicological sciences. 2016; 149:167-177.
30. Hanauske A-R, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anti-Cancer Drugs. 1992; 3:121-124.
31. Ohta K, Ito Y, Miyanaga T, Dohden K, Hayashi H, Hattori M, Hosokawa O, Takeda T, Kaizaki Y, Kiya T. [Effects of preoperative systemic chemotherapy with respect to expressions of hormone receptors and HER2/neu]. Gan to kagaku ryoho Cancer & chemotherapy. 2008; 35:2363-2366.
32. Guarneri V, Frassoldati A, Bruzzi P, D'Amico R, Belfiglio M, Molino A, Bertetto O, Cascinu S, Cognetti F, Di Leo A. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2-positive breast cancer (Short-HER Trial; NCT00629278). Clinical breast cancer. 2008; 8:453-456.
33. Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2014:JCO. 2014.2056. 7479.
34. Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, Roman L, Pedrini JL, Pienkowski T, Knott A. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New England Journal of Medicine. 2012; 366:109-119.
35. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: Gene expression and platinum resistance (Review) parameters in human breast cancer. International journal of molecular medicine. 2004; 14:959-970.
36. Fujii Y, Nakayama M. Reduction of postoperative nausea and vomiting and analgesic requirement with dexamethasone in women undergoing general anesthesia for mastectomy. The breast journal. 2007; 13:564-567.
37. Machuca C, Mendoza-Milla C, Córdova E, Mejía S, Covarrubias L, Ventura J, Zentella A. Dexamethasone protection from TNF-alpha-induced cell death in MCF-7 cells requires NF-kappaB and is independent from AKT. BMC cell biology. 2006; 7:9.
38. Lien HC, Lu YS, Shun CT, Yao YT, Chang WC, Cheng AL. Differential expression of glucocorticoid receptor in carcinomas of the human digestive system. Histopathology. 2008; 52:314-324.
39. Duma D, Jewell CM, Cidlowski JA. Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. The Journal of steroid biochemistry and molecular biology. 2006; 102:11-21.
40. Mattern J, Büchler MW, Herr I. Cell cycle arrest by glucocorticoids may protect normal tissue and solid tumors from cancer therapy. Cancer biology & therapy. 2007; 6:1341-1350.
41. Wu W, Pew T, Zou M, Pang D, Conzen SD. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. Journal of Biological Chemistry. 2005; 280:4117-4124.
42. Dong Z, Yang L, Lai D. KLF5 strengthens drug resistance of ovarian cancer stem-like cells by regulating survivin expression. Cell proliferation. 2013; 46:425-435.
43. Liu R, Shi P, Nie Z, Liang H, Zhou Z, Chen W, Chen H, Dong C, Yang R, Liu S, Chen C. Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression. Theranostics. 2016; 6:533-544.
44. Schneider CC, Gibb RK, Taylor DD, Wan T, Gerçel-Taylor ç. Inhibition of endometrial cancer cell lines by mifepristone (RU 486). Journal of the Society for Gynecologic Investigation. 1998; 5:334-338.
45. Lin VC, Aw S, Ng E, Ng EH, Tan MG. Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues. British journal of cancer. 2001; 85:1978.
46. Chen C, Sun X, Ran Q, Wilkinson KD, Murphy T, Simons JW, Dong J-T. Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene. 2005; 24:3319-3327.